Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization of Hyaluronic Nasal Spray

Inclusion criteria

• Healthy research participant
• Age range between 18 and 70 years.
• Gender: female and male.
• Phototype (Fitzpatrick): I to IV.
• Agree to adhere to the requirements of the study in the fight against the COVID-19 pandemic, through preventive measures: use a mask according to WHO guidelines; use the mask while traveling to the research center and during the study procedures; maintain social distancing; wash hands frequently with soap and/or alcohol gel and go to the research center only at scheduled times to avoid agglomerations.
• Agree not to wet the site during the entire test period;
• Understand the test procedures and agree to their adherence to the study requirements;
• Absence of inflammatory dermatoses or tattoo at the application site;
• Signing of the Free and Informed Consent Term (FICT).

Exclusion criteria

• Pregnancy, lactation;
• Participants with hyperthermia (body temperature greater than or equal to 37.5ºC);
• Participants who have been diagnosed with COVID-19 by RT-PCR exam or by the presence of IgM antibodies in the serology exam, in the last 4 weeks or who are presenting the following symptoms: dry or productive cough, sneezing, runny nose, body pain , headache, anosmia (loss of smell), ageusia (loss of taste) and/or any other symptom that may be related to covid-19 at the discretion of the investigator;
• Participant who belongs to the risk group for COVID-19, that is, with cardiovascular, renal and chronic respiratory problems, immunosuppressed or other conditions that the doctor judges as belonging to the risk group;
• Participants with heart disease (eg, but not limited to: atrial fibrillation, obstructive coronary artery disease);
• Participants with renal and/or neurological diseases;
• Participants with severe or decompensated lung and/or respiratory diseases;
• Use of corticosteroids, antihistamines and/or anti-inflammatory drugs;
• Presence of localized or generalized skin diseases;
• Presence of active inflammatory dermatoses in the test region;
• Frequent exposure to the sun or tanning beds;
• Have participated in an allergenicity study within a period of less than four weeks from the beginning of the study;
• Research participants with a history of allergy to the material used in the study;
• Atopy history;
• History of pathologies aggravated or triggered by ultraviolet radiation;
• Immunodeficiency carriers;
• Forecast of intense sun exposure or tanning session during the study period;
• Forecast to take a bath in the sea, swimming pool or sauna during the study;
• Research participants who practice water sports;
• Research participants with dermographism;
• Use of the following topical or systemic medications: immunosuppressants, antihistamines, non-steroidal anti-inflammatory drugs, and corticosteroids up to 2 weeks before selection;
• Treatment with acidic vitamin A and/or its derivatives orally or topically up to 1 month before the start of the study;
• Aesthetic and/or dermatological body treatment up to 03 weeks before selection;
• Vaccination forecast during the study or up to 03 weeks before the study;
• Any condition not mentioned above that, in the opinion of the investigator, could compromise the evaluation of the study;
• History of non-adherence or unwillingness to adhere to the study protocol;
• Professionals directly involved in carrying out this protocol and their families.
• Be participating in some other study at the moment.
• Any condition that, in the opinion of the researcher, could compromise the study.